Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aldeyra Therapeutics

6.27
-0.3950-5.93%
Volume:257.66K
Turnover:1.66M
Market Cap:374.37M
PE:-6.68
High:6.69
Open:6.69
Low:6.22
Close:6.67
Loading ...

Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA

MT Newswires Live
·
18 Nov 2024

Aldeyra says FDA accepts reproxalap NDA, AbbVie deal expanded to $100M

TIPRANKS
·
18 Nov 2024

Aldeyra Therapeutics Inc: Abbvie Has Also Independently Initiated Certain Pre-Commercial Planning Activities

THOMSON REUTERS
·
18 Nov 2024

Aldeyra Therapeutics: Will Initiate Certain Pre-Commercial Activities, 60% of Which Will Be Paid by Abbvie, 40% by Co IF Option Is Exercised

THOMSON REUTERS
·
18 Nov 2024

Aldeyra: Abbvie Agreed to Amend Expiration of Option to 10 Business Days From Date of FDA Approval, IF Any, of Reproxalap for Dry Eye Disease

THOMSON REUTERS
·
18 Nov 2024

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands Abbvie Option Agreement

THOMSON REUTERS
·
18 Nov 2024

Aldeyra Therapeutics Inc - Pdufa Date Set for April 2, 2025

THOMSON REUTERS
·
18 Nov 2024

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Business Wire
·
18 Nov 2024

Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?

Zacks
·
12 Nov 2024

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Business Wire
·
31 Oct 2024

Aldeyra Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
31 Oct 2024

Aldeyra Therapeutics Resubmits New Drug Application for Dry Eye Disease Treatment Candidate

MT Newswires Live
·
03 Oct 2024

BUZZ-Aldeyra up after resubmitting application for eye disease drug

Reuters
·
03 Oct 2024

Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment

Dow Jones
·
03 Oct 2024

Aldeyra Therapeutics Inc - FDA Review of Nda Resubmission Expected Within 6 Months

THOMSON REUTERS
·
03 Oct 2024

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

THOMSON REUTERS
·
03 Oct 2024